Establishment Labs Recruits Hani Zeini as an Exclusive Advisor

Hani Zeini has joined Establishment Labs Holdings Inc. as an advisor, working under a multiyear contract to help the company enter the U.S. market. 
 
“I have known Hani for many years and can think of no one better to help our team enter the US market,” Establishment Labs Founder/CEO Juan José Chacón-Quirós said. “His experience will be invaluable as we seek to lead the US market and access new groups of consumers with our differentiated and disruptive solutions in breast aesthetics and reconstruction.”
 
Zeini founded Sientra in 2006 and has more than 30 years of experience in the pharmaceutical and medical device industries, including over two decades in aesthetics and plastic surgery. Prior to Sientra, he was executive vice president of Inamed and head of Aesthetics (now part of Abbvie/Allergan Medical), where he was responsible for both the Breast Aesthetics and Facial Aesthetics businesses. In 2017, Zeini founded a boutique advisory firm, Elissar Advisors, focused on providing commercial expertise in aesthetics medicine. 

Zeini earned a bachelor of science degree in electrical and computer engineering from the University of Miami in Coral Gables, Fla. He also completed the Stanford Executive Program at Stanford University Graduate School of Business.
 
“I am beyond excited to help Establishment Labs usher in a new era in plastic surgery, something to which I have dedicated my career,” said Zeini. “Establishment Labs has created the most advanced technologies in breast aesthetics and reconstruction and the company is transforming these markets with a platform that empowers women to take full control of their choices. The U.S. clinical data that was released in April and over a decade of data from the international market shows how superior the Motiva Implant product suite truly is. Mía Femtech and Aesthetic BreastRecon are opportunities that can expand these markets by offering new and improved options to women and plastic surgeons. Bringing new technologies to market for breast augmentation and reconstruction has been my passion for decades, and I look forward to supporting the growth of Establishment Labs for many years.”

“With our launch in the U.S. drawing closer, we have considered a variety of approaches to enter the market. In the end, we decided that to remake the perceptions of our industry, we have to build our business in the U.S. from the ground up. Hani’s experience and wisdom will be vital to those efforts,” said Dr. Heather Brennan, Global Head of Markets at Establishment Labs.
 
Establishment Labs Holdings Inc. is a global medical technology company whose initial focus is breast health, principally breast aesthetics and reconstruction. Establishment Labs offers a portfolio of advanced silicone gel-filled breast implants, branded as Motiva Implants that include a number of patented features designed to deliver improved aesthetic and clinical outcomes. Since commercial launch in 2010, more than 2 million Motiva Implants have been delivered to plastic surgeons in over 80 countries. The company also offers or has under development a number of related products and technologies, including the Motiva Flora tissue expander and Mía Femtech, the company’s minimally invasive breast enhancement procedure. In 2018, Establishment Labs received an investigational device exemption (IDE) from the U.S. Food and Drug Administration for the Motiva Implant and began a clinical trial to support regulatory approval in the United States. Motiva Implants are manufactured at the company’s two facilities in Costa Rica.